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2Abstract
Human serum albumin (HSA) is the major protein in blood plasma and is responsible for
circulatory transport of a range of small molecules including fatty acids, metal ions and drugs. We
previously identified the major plasma Zn2+ transport site on HSA and revealed that fatty-acid
binding (at a distinct site called the FA2 site) and Zn2+ binding are interdependent via an allosteric
mechanism. Since binding affinities of long-chain fatty acids exceed those of plasma Zn2+, this
means that under certain circumstances the binding of fatty acid molecules to HSA is likely to
diminish HSA Zn2+-binding, and hence affects the control of circulatory and cellular Zn2+
dynamics. This relationship between circulatory fatty acid and Zn2+ dynamics is likely to have
important physiological and pathological implications, especially since it has been recognised that
Zn2+ acts as a signalling agent in many cell types. Fatty acid levels in the blood are dynamic, but
most importantly, chronic elevation of plasma fatty acid levels is associated with some metabolic
disorders and disease states – including myocardial infarction and other cardiovascular diseases.
In this article, we briefly review the metal-binding properties of albumin and highlight the
importance of their interplay with fatty acid binding. We also consider the impact of this dynamic
link upon levels and speciation of plasma Zn2+, its effect upon cellular Zn2+ homeostasis and its
relevance to cardiovascular and circulatory processes in health and disease.
Abbreviations: ACB, albumin-cobalt-binding; ATCUN, amino-terminal copper and nickel; BSA,
bovine serum albumin; CVD, cardiovascular disease; DTT, dithiothreitol; FFA, free fatty acid;
HRG, histidine-rich glycoprotein; HSA, human serum albumin; IMA, ischemia-modified albumin;
ITC, isothermal titration calorimetry; LDL, low density lipoprotein; MI, myocardial ischemia; MBS,
multi-metal binding site; PKC, protein kinase C; VSMC, vascular smooth muscle cell.
31. Introduction
Zinc is recognised as an important micronutrient [1,2]. At least 10% of all human proteins require
a structural or catalytic zinc cofactor [3]. In addition, zinc acts as an intracellular and extracellular
signalling agent [4]. In consequence, zinc is involved in virtually every conceivable biological
process, and thus the organismal zinc status affects for example, growth and development, the
immune system, mental health, as well as cardiac health. It must also be noted that zinc, as the
free Zn2+ aquo-ion, is toxic to cells at very low concentrations [5]. Given its ubiquity, essentiality
and potential cell toxicity, cellular zinc homeostasis [6,7] is usually well-controlled, involving no
less than 24 membrane-bound transporters of the ZIP and ZnT families [8], and at least 13
expressed metallothioneins [9]. Alterations in zinc homeostasis are known to occur with
increasing age [10], and in some of the most prevalent diseases [11], including
neurodegenerative diseases, cancer, diabetes and cardiovascular disease (CVD) [12]. In many
cases, it has remained obscure whether these alterations are cause or consequence, or both, of
the respective disease state, and occasionally, it is even unclear whether the observed alterations
are harmful or beneficial.
Mammalian zinc homeostasis on the organismal level also involves the circulatory system [13].
Although zinc plasma levels (reference values are around 16.6±6.2 M [14]) are affected by a
range of conditions ([15], also see section 4), they are not decreased by mild zinc deficiency [16].
This suggests that plasma zinc levels are also subject to tight control – and it is important to
understand how this control works. Apart from the crucial importance of ZIP and ZnT
transporters, it is conceivable that this is also influenced by Zn2+ binding to components of plasma
– and chief amongst these is serum albumin [17]. Our studies have revealed that albumin directly
links plasma zinc and free fatty acid (FFA) dynamics through allosteric binding. In the present
review, we will explore how this allosteric link may impact on cardiovascular health and disease.
Our findings also have direct implications for the diagnostics of myocardial ischemia through the
biomarker "ischemia-modified albumin" (IMA), and since there is much confusion in the current
4literature regarding this, we will begin with a summary of the current state of the art on metal ion-
albumin interactions.
2. The multi-metal binding site on serum albumin and its allosteric regulation by fatty
acids
Albumin is not only the most abundant plasma protein (ca. 640 M; 40 g/L), but under normal
conditions also binds the vast majority of exchangeable plasma Zn2+ [18]. Metal binding to
mammalian serum albumins has been studied for several decades [19], and it is now clear that
most albumins harbour at least four distinct metal-binding sites [20,21]: best known is perhaps the
N-terminal "ATCUN" (Amino-Terminal Copper and Nickel) binding motif [22], followed by two sites
detectable by 113Cd NMR spectroscopy, called site A and B [23-25], and lastly the free thiol of
Cys34 [26]. The latter is only relevant for very thiophilic xenobiotic metal ions such as Au+ [27],
Pt2+ [28] and Hg2+ [29], whereas the former three sites are capable of binding a range of 3d metal
ions including Cu2+, Ni2+, Co2+, Mn2+ and Zn2+.
These divalent metal ions and Cd2+ display different preferences for the ATCUN site, site A and
site B. Taking advantage of the Jahn-Teller effect, the d8 and d9 ions Ni2+ and Cu2+ show a
distinct preference for the square-planar geometry provided by the ATCUN motif [22,30,31]. This
binding mode involves the unprotonated terminal amino group and the imidazole side-chain of
His3, and requires the deprotonation of two backbone amides. Both Cu2+ and Ni2+ can elicit this
deprotonation at physiological pH, but Zn2+ and Co2+ require a much higher pH to effect
significant binding to model peptides [32]. Instead, the closed-shell Zn2+ ion prefers the distorted
site A [23,24,33] (dissociation constant KD = 0.3-40 M [34-37]), and the highest affinity site for
Co2+ (high-spin d7) has been determined as site B (KD = 11 M [38]), followed by site A (90 M)
and, lastly, ATCUN (110 M) [38]. Cu2+ binds with picomolar affinity to the ATCUN site [31], and
with a KD = 10 nM to site A [39]. The respective values for Ni2+ are 150 nM [40] and 12.5 M [41].
5Site A has also been termed the multi-metal binding site (MBS) [39,41]: whilst it is a primary site
for Zn2+ and Cd2+, it is a secondary site for Cu2+, Ni2+ and also Co2+. This means that whenever
more than one equivalent of the latter ions are added to pure, ligand- and metal-free albumin, this
site will become significantly occupied by the respective metal ion. It is also important to note that
in human and bovine serum albumin (HSA and BSA), Cu2+ still forms stronger interactions with
this site than either Cd2+, Ni2+ Co2+, or Zn2+ [40]. This is in keeping with expectations based on the
Irving-Williams series, which describes the order of affinities of divalent high-spin complexes [42].
The location [33] and structure [43] of the major zinc site (and hence the secondary site for Co2+,
Ni2+, and Cu2+) have been determined using a range of spectroscopic techniques, although no X-
ray crystallographic studies on any Zn-albumin complexes are as yet available. The most striking
peculiarity of this site is its location at the domain interface between domain I and domain II of
HSA (Figures 1a and b). It is formed by two residues from each domain: His67 and Asn99 from
domain I and His247 and Asp249 from domain II. These four residues are conserved in albumins
from mammals. A copious amount of X-ray crystallographic studies have been carried out on
HSA [44-53], with structural information on other serum albumins having become available
recently [54,55]. Inspection of these structures reveals that the MBS is consistently only present
in fatty acid-free preparations [33] (Figure 1c). Fatty acids are the primary ligands for albumin,
and albumin is the primary plasma transporter for long-chain unesterified (or "free") fatty acids
(FFA), which are the primary source of energy for the myocardium. The origin of disruption of the
MBS is traceable to the FFA binding site FA2 [46], which significantly also requires interacting
residues from both domains I and II (Figure 1d). Although there is no overlap between the zinc-
and fatty-acid binding residues, the domain-domain movement that is required to form the FFA
binding pocket essentially leads to the destruction of the preformed zinc-binding site [33]. This
observation raised the question whether zinc binding inhibited fatty acid binding to this site, or
vice versa. Isothermal titration calorimetry (ITC) studies involving the ternary system BSA, Zn2+
and myristate clearly demonstrated that the C14 fatty acid inhibited zinc binding to albumin
6(Figure 2d) [37]. Recent studies confirmed that fatty acids inhibit zinc binding to the MBS also in
HSA (Figure 2a) [56].
This allosteric switch is expected to have multiple physiological consequences, further described
in sections 3 and 4. Under normal conditions, between 0.1 and 2 FFA molecules are carried per
albumin molecule [19,57], but there a number of conditions, including fasting, extreme exercise
[58], obesity, metabolic syndrome, diabetes mellitus, and cardiovascular disease [59] including
atherosclerosis and myocardial infarction [60], under which up to four [19], or even more [61],
FFA molecules can become bound. Importantly, many of these conditions are also associated
with considerable shifts in plasma zinc levels, and these observations, together with our structural
and thermodynamic studies, have led us to hypothesise that these correlations are mediated by
HSA [15] - the main transporter for both zinc and FFAs in plasma. However, it should be stressed
that FFA effects on zinc speciation and distribution are not expected to be restricted to such
drastic conditions - we observed marked differences in zinc affinity and binding capacity even at
just 1 molar equivalent of myristate for both BSA and HSA (Figures 2a and b) [37,56]. This is
consistent with observations by the group of Hamilton that indicated that FA2 is one of the
highest-affinity FFA binding sites on HSA [62,63].
One further momentous implication of this allosteric switch is based on the fact that MBS is, as
mentioned earlier, also a secondary binding site for other M2+ metal ions. This simply means that
the Co2+ (and Cu2+ and Ni2+) binding capacity and affinity of albumin will also be affected by fatty
acid levels, and for Co2+, this has indeed been demonstrated (Figure 2e). Myocardial ischemia is
one of the many conditions in which FFA levels are significantly elevated. Hence, the FFA-
mediated allosteric switch also effortlessly explains the reduction in metal binding in diagnostic
tests related to the Albumin-Cobalt-Binding (ACB) test [64,65], as well as the identity of the
elusive biomarker "Ischemia-Modified Albumin" (IMA): IMA is simply albumin with a higher ratio of
7FFA bound. The case for this assertion, as well as ensuing implications, will be laid out in section
5.
3. FFA-mediated alterations in plasma zinc speciation: Implications for neutralisation of
heparins
Zinc is an important regulator of coagulation following its release from activated platelets [66].
The resultant local increases in Zn2+ concentration are sensed by a range of haemostatic proteins
to stimulate a pro-coagulatory response [67]; this represents an essential transition phase that
promotes the propagation of coagulation. Plasma proteins that bind Zn2+ under these conditions
include histidine-rich glycoprotein (HRG), a key effector molecule upon which Zn2+ acts to
regulate coagulation [68,69]. HRG is a 75 kDa glycoprotein present at a concentration of 1.3-2.0
μM in adult blood [69,70]. We recently demonstrated that HRG possesses ten Zn
2+ sites (with an
average apparent Kd of ~6 μM) and that Zn2+-binding enhances the ability of HRG to bind and
neutralize long-chain heparins [56]. Under normal conditions heparin binds to and stabilizes the
anticoagulatory antithrombin III/thrombin complex. During clotting, thrombin cleaves fibrinogen
into insoluble strands (fibrin) that are cross-linked by factor XIII to form a blood clot [71]. Zn2+-
dependent neutralization of heparin by HRG provides increased competition for heparin binding
to this complex, which may result in release of thrombin and an increase in its activity, which will
ultimately promote clotting.
Speciation modelling experiments based upon affinity and stoichiometry data for Zn2+-binding to
HRG and to albumin (in the absence and presence of various concentrations of myristate)
suggested that the FFA-mediated reduction in availability of the MBS increases the proportion of
plasma Zn2+ bound to HRG (Figure 2c), such that its ability to neutralize heparins will be
increased [56]. However, it is important to point out that this simple model only considered serum
albumin and HRG and did not take into account other circulatory proteins that could bind
displaced Zn2+. These include other components of the blood-clotting cascade [67], as well as
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also associate with molecules other than heparin (such as tropomyosin, factor XIIa and soluble
IgG) in a Zn2+-dependent manner [69,73], thus the actions of increased Zn2+-binding to HRG are
likely to be complex.
Interestingly, a recent study by Fredenburgh et al. has revealed that fibrinogen, like HRG, also
binds heparin with high affinity in a Zn2+-dependent manner [74]. Fibrinogen is a glycoprotein
present in plasma at a concentration of around 6-12 μM [71,75]. The study by Fredenburgh et al.
revealed that Zn2+ binds fibrinogen with a Kd in the low micromolar range; values of 9.4 μM and 
4.5 μM were measured using surface plasmon resonance and a fluorescence-based assay, 
respectively. Furthermore, they found that Zn2+ promotes a 4-fold increase in heparin binding to
fibrinogen. This study highlights the fact that Zn2+ can potentially influence heparin neutralization
by fibrinogen as well as by HRG. Also a further reduction of heparin activity will occur when
fibrinogen is clotted because heparin promotes thrombin binding to fibrin and induces the
formation of a complex that limits inhibition by antithrombin [76,77]. Zinc also stimulates platelet
aggregation by promoting fibrinogen binding to αIIbβ3, its cognate receptor on the platelet surface
[66,78].
The observations above are particularly interesting as disorders characterized by chronically
elevated levels of plasma fatty acids are associated with an increased risk of thrombosis [79,80].
These include obesity [81,82], diabetes [83], fatty liver disease [84], and cancer [85]. For
example, thromboembolism (caused by obstructive blood clots) is the second leading cause of
death associated with malignancy [79]. Collectively, these observations suggest that under
conditions where FFA levels are elevated, Zn2+ displaced from serum albumin could bind HRG or
fibrinogen to enhance their respective interactions with heparins and induce a pro-coagulatory
effect [86], as summarized in Figure 3. In older adults, this may be further compounded as
plasma albumin levels are known to decrease with age [87]. An age-related decrease in plasma
9albumin also correlates with an observable increase in the ratio of FFAs per albumin molecule
[88]. It is important to point out that the degree to which each of the respective proteins, HRG and
fibrinogen, contribute to Zn2+-dependent neutralization of heparins remains to be determined.
However, evidence for a direct link between defective plasma Zn2+-handling, mediated by FFA-
displacement of Zn2+ from albumin, and thrombotic risk is compelling.
4. Cellular effects of altered plasma zinc speciation and cardiovascular disease
A number of studies have examined the association of zinc with coronary diseases,
cardiomyopathies and arrhythmias, and links between etiopathogenesis of CVD have been
suggested [89-91]. Aberrant Zn2+-homeostasis is associated with cardiomyopathy including
chronic heart failure and myocardial damage [11,89], as well as primary arterial hypertension
[92,93]. Many intracellular enzymes and other proteins involved in regulating cardiac function are
Zn2+-dependent [89]; furthermore, zinc homeostasis and intracellular redox balance are intimately
linked [6,94]. Therefore, the impact of zinc on cardiovascular health is most probably
multifactorial; some potential mechanisms and pathways are discussed in this section.
Potential impact of albumin on cellular zinc homeostasis
Intracellular zinc concentrations are known to be regulated largely by zinc transporters, zinc
binding proteins including metallothioneins, and zinc sensors [6,7], but the extracellular space
also participates in zinc dynamics. Indeed, various studies have suggested that serum albumin
helps to regulate the uptake of Zn2+ by a range of cell types. For example, serum albumin
facilitates the uptake of Zn2+ into endothelial cells [95] and erythrocytes [96]. Also receptor-
mediated vesicular co-transport of Zn2+ with albumin across the endothelium has been
demonstrated in vitro [97]. Despite this, any direct role for albumin in mediating delivery of Zn2+ to
cells via endocytosis is likely to be relatively minor as only ~2% of circulating albumin molecules
carry Zn2+ at any one time. The primary function of albumin in mediating Zn2+ uptake is through
maintenance of the plasma exchangeable zinc pool. Ultimately, Zn2+ will cross cell membranes
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predominantly through ZIP (transport from plasma into cells) and ZnT (transport into plasma)
transporters. Crucially, the activity of these transporters depends on availability of free Zn2+ – and
this in turn is regulated by the assortment of molecules that can reversibly bind Zn2+ in plasma. If
the zinc-binding capacity of plasma drops, this may lead to an increase in free Zn2+ (Figure 2b),
which should, in the first instance, result in increased cellular uptake. This may manifest in
decreased levels of plasma zinc. Intriguingly, the same conditions that are associated with high
FFA levels, including congestive heart failure, myocardial ischemia and infarction, are also known
to result in decreased plasma zinc [98,99] – more precisely, exchangeable, albumin-bound zinc
[100,101]. This is consistent with the idea that in these conditions, the increased FFA levels lead
to lower zinc-binding capacity by albumin, and an increase in free Zn2+ available for cellular
uptake. We hypothesise that conditions that lead to elevated plasma FFA might cause significant
changes to cellular zinc homeostasis, at the very least in cells in direct contact with plasma,
including erythrocytes, platelets, macrophages, B- and T-cells, endothelial cells, but potentially
also vascular smooth muscle cells (VSMC) and cardiomyocytes. Based on the facts that both a
lack of zinc [102] as well as excessive extracellular free Zn2+ [5] has deleterious effects on cells in
general, any large perturbation of plasma zinc homeostasis may be expected to have direct or
indirect detrimental consequences for cells. Some possible effects are described below.
Effects of zinc on intracellular calcium signalling in cardiomyocytes
Ca2+ is crucially involved in the function of cardiomyocytes and VSMCs [103], with intracellular
Ca2+ release from the sarcoplasmatic reticulum through ryanodine receptors triggering the
contraction of these muscle cells [104]. CVD has been linked to dysregulated intracellular Ca2+
release, reduced cardiac contractility and prolonged rises of systolic Ca2+ [105]. There is cross-
talk between the fluxes of Ca2+ and Zn2+ [106]; hence, it is thought that zinc dyshomeostasis will
impact on Ca2+ trafficking in cardiomyocytes (as recently reviewed in [107]). Various studies
suggest that defective Zn2+ handling contributes to cardiomyopathies including altered
contractility and heart failure [89,108-110]. Indeed, it has been hypothesised that increased
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cytosolic Zn2+ can influence cardiac excitation-contraction coupling through regulation of the
ryanodine receptor in cardiomyocytes [111,112]. The combined effects of Zn2+ and Ca2+
dyshomeostasis are also thought to generate oxidative stress, lead to cardiac myocyte necrosis
and replacement fibrosis [113].
Blood pressure effects of zinc
Changes of both intracellular and extracellular zinc contents have been documented for primary
arterial hypertension [92,93]. Serum zinc levels are decreased in arterial hypertension, as are
those in lymphocytes and bone, whereas zinc levels in erythrocytes, heart, liver, kidney and
various glands are increased; overall, the organism becomes zinc-deficient. It has remained
unclear whether this systemic zinc dyshomeostasis is cause or consequence of arterial
hypertension. Lower plasma zinc levels are suggested to impact on Ca2+ fluxes, and the activities
of angiotensin-converting enzyme (ACE), endothelin-converting enzyme, and neutral
endopeptidase. Increased erythrocyte zinc is associated with increased carbonic anhydrase
activity, which may result in increased blood pH. Angiotensins are vasoconstrictors; thus a
decrease in ACE activity leads to increased levels of angiotensins and hence increased blood
pressure. Also endothelial NO-synthase (eNOS) is involved in the generation of the vasodilator
NO, hence important for the regulation of blood pressure. eNOS contains a structural zinc site
that is essential for enzyme function; its disruption by reactive oxygen and nitrogen species has
been demonstrated [114]. Thus, zinc dyshomeostasis may either directly or indirectly affect its
activity, with a lack of zinc expected to lead to decreased NO levels and hence increased blood
pressure.
Zinc dyshomeostasis in atherosclerosis
The major underlying mechanism in the development of CVD is the formation of atherosclerotic
plaques in the wall of blood vessel which eventually leads to stroke, heart attack and lower limb
disease [115,116]. There is much evidence that zinc deficiency is pro-atherogenic [117]. A
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number of pathways have been invoked to explain this correlation, as summarized in Figure 4.
For example, inflammation is known to play a major role in the development of atherosclerosis
[118]. Zinc has been shown to impact on several of the molecules that have been implicated in
this etiology. For instance, the zinc-dependent [119] transcription factor NF-кB, a key element in 
regulation of inflammatory responses [120] may in many cells be regulated by Zn2+ status [121].
NF-кB regulates amongst others the expression of vascular cell adhesion molecule (VCAM)-1, 
ICAM-1, E-selectin, cytokines of the interleukin family, plasminogen activator inhibitor (PAI)-1,
and inducible nitric oxide synthase (iNOS). Cytokine transcription is also directly regulated by zinc
[122], and several cytokines (IL-β, IL8 and TNF-α) themselves induce expression of E-selectin, 
ICAM and VCAM. This results in trapping of monocytes, platelets, neutrophils and erythrocytes,
which subsequently block blood vessels.
Zinc also impacts on various other signalling networks, including those involving protein kinase C
(PKC), which plays a central role in many signalling pathways in endothelial and vascular smooth
muscle cells [123]. Thrombin, angiotensin and endothelin all trigger the activation of PKC, via
signalling cascades involving G-protein-coupled receptors and phospholipase C. The latter
hydrolyses phospholipids, and the resulting diacylglycerols activate PKC [89,124]. PKC contains
a redox-sensitive zinc-binding site, and it is thought that through this site, the cellular redox state
regulates the activity of PKC [89]. The link between zinc and cellular redox state is well
established [6]. PKC plays an important role in proteoglycan synthesis. Proteoglycans are
components of the extracellular matrix. Their composition has been shown to be critical for lipid
retention, and hence, atherosclerosis [125]. Thus, modulating PKC activity by Zn2+ will in turn
regulate various vasoactive factors that ultimately impact on the development of atherosclerosis.
Another group of zinc-dependent enzymes critically involved in the extracellular matrix are the
matrix metalloproteinases. They are implicated in the response to inflammation [126], and
regulate the bioavailability and activity of cytokines, chemokines, and growth factors. They
degrade the extracellular matrix, cell surface components as well as intracellular proteins, and are
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therefore particularly important for vascular and cardiac tissue remodelling, both in normal
conditions but also, e.g., during the development of atherosclerosis [127] and the adverse
structural remodelling of the myocardium [128]. In atherosclerosis, they may either stabilise or
promote rupture of plaques, and hence contribute to acute myocardial infarction [129]. Since they
require a zinc cofactor, their activity may be modulated by zinc dyshomeostasis, although no
detailed studies on this hypothesis are available.
In addition, a lack of zinc is associated with apoptosis in many cell types [130]. Endothelial cell
injury and apoptosis is a defining event in atherosclerosis [131], and it is thought that oxidative
stress resulting from lipid peroxidation and the action of inflammatory cytokines is a major
contributor to these processes [11]. Zinc has both anti-inflammatory and anti-oxidant effects
[132], and it has been suggested that Zn2+ performs a crucial role in maintaining the integrity of
endothelial cells [121]. Thus it is possible that chronically lower plasma levels contribute to
endothelial cell apoptosis. In contrast, long-term zinc deprivation has also been shown to
accelerate rat VSMC proliferation via down-regulation of the JNK1/2 pathway [133]. Accelerated
VSMC proliferation is a contributing factor in development of atherosclerosis through thickening of
the vascular wall [134].
Finally, one may also consider the effects of increased free extracellular Zn2+. Although the anti-
inflammatory function of dietary zinc has been mentioned, the direct action of Zn2+ on vascular
endothelial cells induces inflammation [135]. Induction of senescence by Zn2+ of VSMCs has also
been reported, and it is thought that this is mediated through angiotensin [136]. More drastically,
cell survival of primary cultures of cardiomyocytes was negligible at only 0.6 M free Zn2+ [5].
5. FFA-loading of albumin as the molecular basis of ischemia-modified albumin
Ischemia-modified albumin (IMA) is a biochemical marker of myocardial ischemia (MI) for the
detection and the early diagnosis of acute coronary syndromes [137]. IMA can be measured
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using the albumin-cobalt-binding (ACB) assay, which was first established by Bar-Or et al. [138].
The ACB assay has a high negative prognostic value, which is useful in rapidly excluding
ischemia as a cause of chest pain [65,139]. Despite this, the specificity of the test is low, with
increased IMA values also characteristic of various other conditions including fatty liver, cancer,
infections, renal disease, preeclampsia, diabetes, stroke, and even sustained exercise [140-145].
The basic principle of this test is such that following an ischemic event, serum albumin is
somehow chemically modified such that its ability to bind Co2+ is compromised. As a quantitative
analytical method, the ACB test is performed by the addition of CoCl2 to a patient plasma sample,
followed by the addition of dithiothreitol (DTT) to complex the portion of Co2+ that has remained
unbound to serum albumin, and finally detection of a brown color corresponding to formation of
the Co-DTT complex [138].
The molecular basis for IMA and what it exactly is has remained controversial. For some time it
was incorrectly assumed that the primary Co2+ binding site on albumin is at the N-terminus and
that ischemia leads to the cleavage of the first two residues or some other oxidative modification
such that this metal binding site is effectively removed [64,146]. However, several efforts to prove
a correlation between N-terminal modification and positive ACB assay have failed repeatedly
[139,146,147]. Moreover, several in-vitro metal binding studies since 2007 concluded that the N-
terminal ATCUN site is not the primary Co2+-binding site [38,148,149].
Based on our identification of the location of MBS and its allosteric regulation by fatty acids [33],
Mothes and Faller hypothesised in 2007 that the reduced Co2+ binding of IMA may be related to
fatty-acid inhibition of Co2+ binding to the MBS [148]. Soon after, based on the observation that
plasma concentrations of FFAs rise during MI [150,151], a relationship between FFAs and the
reversible generation of IMA was suggested [144], and Bhagavan et al. found a "plausible but not
causative relationship" between IMA levels and FFA levels in the sera of patients with acute
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myocardial infarction relative to controls, whereby an increase in FFA levels resulted in a lower
Co2+-binding capacity, and hence an increase in IMA [60]. This explains why positive ACB tests
are also found in a plethora disorders unrelated to MI, but which are associated with increased
plasma concentrations of FFAs [141,142,144,145].
Crucially, plasma FFAs are predominantly bound to albumin in the circulation [152]. Based on our
previous work where we demonstrated interactive binding of FFAs and Zn2+ at the MBS [33,37],
we examined the effects of FFAs on Co2+ binding to albumin in vitro [149]. The results of this
study revealed that physiologically relevant concentrations of the long chain FFA myristate were
sufficient to reduce the Co2+-binding affinity and capacity of bovine serum albumin [149], in a
manner broadly similar to that of Zn2+ [37]. Myristate binding to BSA was shown to inhibit metal
binding to both sites A (MBS) and B [37,149] (with the latter being the primary Co2+ binding site
[38]), resulting in a decrease in total Co2+-binding site availability and a corresponding increase in
Co−DTT complex formation in the ACB assay [149] (Figures 2e and 2f). The results of this work, 
taken together with the already established link between elevated plasma FFA levels and MI
[60,144,150,151], strongly suggest that IMA corresponds to albumin with increased levels of
bound FFAs and not N-terminally modified albumin. These observations have important
implications for the detection of MI as they suggest that “IMA” is strictly speaking neither a marker
for ischemia nor oxidative stress, but a proxy measurement of plasma FFA levels.
Even though hypotheses based on permanent covalent modifications are incompatible with the
rapid clearance of IMA within hours of the ischemic event - serum albumin has a circulating half-
life of 19 days! - and even though a 2012 study by Oh et al. categorically stated an "Insignificant
role of the N-terminal cobalt-binding site of albumin in the assessment of acute coronary
syndrome" - and even though our own 2012 study had offered experimental evidence supporting
a coherent molecular mechanism that is compatible with all clinical observations [149], many
researchers working in this area appear ignorant to this collective evidence, with a host of recent
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publications perpetuating the myth of N-terminal modification of albumin being the basis for the
assay [153-155]. Very recently Eom et al., acknowledging that the N-terminus is not the primary
Co2+ binding site but still convinced that the N-terminus of IMA is modified, even attempted to
improve the ACB assay through use of Cu2+ (rather than Co2+) [153], which has been known for
many years to bind strongly to albumin at the N-terminus [20,22,38,39]. This new test was
employed with success, as was a previous attempt by others to use binding of Ni2+ (the first
equivalent of which also binds at the N-terminus) as the basis of the assay [156]. In each case
the metal ion (either Cu2+ or Ni2+) bound, like Co2+, less effectively to IMA than control albumin
[153,156]. However, the concept of Cu2+ and Ni2+-binding to albumin also being influenced by
FFA-loading is not surprising as 113Cd-NMR and other spectroscopic studies previously revealed
the multi-metal site to be a strong secondary binding site also for these metal ions following
saturation of the N-terminal site [20,39,40]. Therefore, as long as the metal ion is added in excess
over albumin, MBS will act as a sensor for plasma FFA for all three M2+ mentioned. Indeed, in the
original ACB assay, 140 M Co2+ and 90-100 M albumin are present [138]. In the nickel-based
test, there was a 3-fold excess of Ni over albumin [156], whereas we were unable to establish the
Cu:albumin ratio in the copper-based test. We also note that site B, the primary Co2+ binding site,
is also FFA-responsive in BSA [37,149]; whether this is also the case for HSA has not yet been
established conclusively.
These observations are not meant to bring these important diagnostic tests into disrepute; our
main motivation for this discussion is the desire that the molecular basis for the test be well and
truly understood. IMA can be detected within minutes of an ischemic event, and remains the only
marker for the early detection of MI. We strongly believe that metal-based tests detecting IMA are
valuable and should have their place in modern clinical diagnostics - not only in MI, but other
diseases related to elevated plasma FFA. Indeed, a recent study has established that IMA is a
better prognostic marker than other biomarkers for peripheral arterial occlusive disease [157].
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Conclusions
CVD represents colossal challenges due to its huge health burden on society. The importance of
metals as dietary factors and essential inorganic micronutrients capable of modifying CVD has
come to prominence only recently; hence, guidelines from the national heart associations at
present are mostly silent on the relation between CVD and metal ions [89]. When the levels of
circulatory trace metals in blood become depleted, nutrient metals absorbed from the diet are
actively transported into blood and from there to cells as needed. However, abnormalities in the
ratios and levels of trace metals will likely develop when this system fails. Although albumin
chemistry is of undoubted importance in controlling the circulatory exchange of such metals (and
other ligands), many features of its chemistry are yet to be fully understood. Here we have
attempted to illustrate this by examining the interplay between the MBS and FFA binding to
albumin. It is apparent that the interactive binding of Zn2+ (and other metals that bind at this site)
and long-chain fatty acids has potential physiological and clinical consequences. This is
highlighted in the discovery that IMA represents FFA-loaded albumin and that the ACB assay is a
proxy measurement of the FFA content of albumin. However despite this, further work is
necessary to fully understand the physiological and pathological importance of elevated FFA
levels and their impact on circulatory metal ion speciation. We envision that the work highlighted
here will motivate others to examine causes and potential downstream effects of altered plasma
metal ion speciation. It is hoped that such studies will enable us to better understand the
molecular relationships that exist between the transport of metabolites and metal ions in plasma
and their relevance to physiological and pathological processes.
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Figure Legends
Figure 1. Structural basis of allosteric binding of zinc and fatty acids to serum albumin. (a)
Location of inter-domain zinc site A (MBS) (b) [43] and fatty-acid binding site FA2 (d) [46]. The
three domains of albumin are shown in grey (domains I and III) and black (domain II). (b) shows a
close-up of the distorted 5+1 metal binding site; the backbone carbonyl oxygen of His247 also
forms a long bond to the Zn2+ ion. In (d), the four zinc-binding residues are shown with thin lines,
and some residues forming the two halves of the FA2 binding pocket are shown as sticks, with
the resolved part of a myristate molecule shown in space-filling mode. (c) MBS residues in a
selection of X-ray structures with and without (pdb 4G03, 2BXH, 4F5V (rabbit SA), 3V09 (rabbit
SA), 3JRY, 1E78, 1AO6, 4K71 (HSA in complex with the Fc receptor) [45,50,51,53,54,55]) bound
fatty acids (decanoate (1E7E), dodecanoate (1E7F), myristate (3SQJ, 1E7G), palmitate (1E7H),
stearate (1E7I), oleate (1GNI), arachidonate (1GNJ) [47,48]). The overlay was generated by
aligning the backbone atoms of residues His247, Gly248, and Asp249 in Swiss pdb viewer v. 3.7.
Figure 2. Impact of fatty acids on binding site availability on albumin for Zn2+ and Co2+ and
consequences thereof. (a) and (d) Myristate-induced reduction in availability of site A (MBS) for
HSA and BSA, as determined by isothermal titration calorimetry [37,56]. (b) and (c) Plasma
speciation modelling suggested that the reduction in binding site availability may result in an
increase of free Zn2+ and zinc bound to HRG [56]. (e) ITC experiments revealed a similar
reduction of overall binding site availability for Co2+ [149]. One out of three possible binding sites
is lost in the presence of 5 mol. equiv. of myristate. ND indicates that no data is available. (f)
Myristate binding to BSA leads to increased Co-DTT complex formation in the ACB assay [149].
The line is drawn to guide the eye and does not represent a fit.
Figure 3. Diagram illustrating the mechanisms by which Zn2+ may influence coagulation through
stimulation of HRG- and fibrinogen-dependent pathways.
36
Figure 4. Schematic illustration showing how elevated plasma FFA levels may influence cell
metabolism such as to impact upon pro-atherosclerotic pathways.
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